ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1776

Anti-SSA/Ro Mediated Injury to the Endothelium Via Urokinase Plasminogen Activator Receptor/Tgfbeta Activation: Implications in the Pathogenesis of Congenital Heart Block

Paraskevi Briasouli1, Mark Halushka2, Jill P. Buyon3 and Robert M. Clancy4, 1Rheumatology, New York University Medical Center, New York, NY, 2Division of Cardiovascular Pathology, John Hopkins Pathology, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 4Medicine, New York University School of Medicine, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Apoptosis, autoantibodies, endothelial cells, inflammation and transforming growth factor

  • Tweet
  • Email
  • Print
Session Information

Title: Cell-cell Adhesion, Cell Trafficking and Angiogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

One mechanism by which anti-Ro antibodies are linked to the pathogenesis of (cardiac-NL) neonatal lupus is the increased urokinase plasminogen activator (uPA)/urokinase-type plasminogen activator receptor (uPAR)-dependent plasminogen activation and subsequent triggering of TGFbeta signaling. Immunologic staining of affected hearts reveals cell specific expression of uPA on endothelial cells and infiltrating macrophages  in areas  of inflammation and fibrosis. Since plasminogen/plasmin-dependent TGFbeta signaling has a documented role in endothelial cell survival, this study evaluated the association of anti-Ro and an injury pathway in the fate of the cardiac vasculature. 

Methods:

Adhesion, tube formation, TGFbeta activation assays were used to assess the effect of antibodies on endothelial cell function. Immunohistology of cardiac-NL autopsies were conducted to evaluate diseased vasculature. 

Results:

Human IgGs were used from a healthy control (nl-IgG) and a mother whose serum contained reactivity to all the components of the SSA/Ro-SSB/La complex and whose child had cardiac-NL (CHB-IgG).  Adherence was enumerated (colorimetric dye) after vascular endothelial cells (CD3 cell line) were incubated with CHB-IgG (0.03 mg/ml, 2 hr) or nl-IgG, with or without plasmin inhibitor aprotinin (10 μg/ml) or TGFbeta inhibitor SB5543 (10μM). CHB-IgG coincubation significantly reduced EC adhesion on ECM (collagen-coated surfaces) compared with nl-IgG (0.38±0.1 vs 0.89±0.09 respectively (adhesion units, scale 0-3), p=0.02, n=3).  The CHB-IgG decreased adhesion was reversed in the presence of either aprotinin or SB5543. Further evidence to implicate a plasmin/TGFbeta axis was provided by the observation that ECs treated with CHB-IgG, but not nl-IgG, increased luciferase activation of a TGFbeta reporter cell line (TMLC) (432±20 vs 138±12 RLU respectively,p = 0.003;n = 3), an effect abrogated by cotreatment with aprotinin or SB5543. Vessel formation was evaluated by visual inspection of networks after ECs were plated on matrigel (8 hr). Exposure of ECs to CHB-IgG but not nl-IgG markedly attenuated blood vessel formation in vitro which again was reversed by cotreatments with aprotinin and SB5543 as observed in the adhesion studies (n=4).  As further proof of concept, during migration of ECs on collagen-coated surfaces, confocal microscopy revealed colocalization of uPAR with anti-Ro60  (but not anti-Ro52 or anti-RNP) at the tips of migrating cells. Evaluation in vivo, showed that in a fetal CHB heart, protein expression of CD31 (a surface marker of endothelium lining blood vessels) was at a substantially lower level in septal regions with involved inflammation when compared with a healthy zone of atrial tissue. 

Conclusion:

These results suggest that anti-SSA/Ro interference during the remodeling events occurring in angiogenesis results in increased uPAR-dependent uPA activity with generation of active TGFbeta.  This then leads to the attenuation of adhesion and new vessel development and ultimately a loss of vasculature in the septal region of affected hearts.


Disclosure:

P. Briasouli,

NIH 1K01AR060302-01A1,

2;

M. Halushka,
None;

J. P. Buyon,

NIH 5R37AR042455,

2;

R. M. Clancy,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-ssaro-mediated-injury-to-the-endothelium-via-urokinase-plasminogen-activator-receptortgfbeta-activation-implications-in-the-pathogenesis-of-congenital-heart-block/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology